Biogen Appoints Camille Lee As SVP Alzheimers Disease Therapeutic Area

(NASDAQ: BIIB) announced the appointment of Camille Lee as Senior Vice
President, Alzheimer’s Therapeutic Area, effective today.

In her new role, Ms. Lee will be responsible for the design and
execution of commercial strategy for the company’s late-stage
Alzheimer’s disease assets and will work in partnership with Biogen’s
Research & Development function in overseeing Biogen’s entire
Alzheimer’s portfolio. She will be based in Cambridge, Mass., and report
directly to Chief Medical Officer Alfred Sandrock, Jr., M.D., Ph.D.

Ms. Lee brings to Biogen more than 30 years of industry experience. In
her most recent role as Senior Vice President, Diabetes & Obesity
Marketing at Novo Nordisk, she led a team of more than 500 professionals
while overseeing the marketing of all in-line and future brands as well
as market access strategy. During her time in this position, Novo
Nordisk successfully launched two brands that achieved leadership in
their therapeutic areas.

Camille’s experience in preparing markets and launching products for
highly prevalent diseases will serve us well as we aspire to move toward
commercializing our late-stage Alzheimer’s disease candidates,” said Dr.
Sandrock. “Her track record aligns perfectly with our mission to deliver
transformative therapies for neurodegenerative diseases to patients who
desperately need them.”

Prior to taking a leadership role for Novo Nordisk’s diabetes and
obesity franchises, Ms. Lee worked across the organization. Her tenure
at Novo Nordisk included positions of increasing responsibility in such
functions as competitor intelligence, product launch planning, and
international marketing for multiple endocrine products.

Biogen’s R&D in Alzheimer’s is an inspiration, and I am honored to be
joining a company that has such an unwavering commitment to the
community,” said Ms. Lee. “I look forward to working with the team as we
aim to bring therapies to the market that could make a difference to the
thousands of patients and their families that we serve.”

Ms. Lee holds a B.S. in Business Administration from California State
University, Long Beach, and an M.B.A. from Copenhagen International
Management Institute.

About Biogen
Through cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative therapies
for people living with serious neurological and neurodegenerative
diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and
today the company has the leading portfolio of medicines to treat
multiple sclerosis; has introduced the first and only approved treatment
for spinal muscular atrophy; and is at the forefront of neurology
research for conditions including Alzheimer’s disease, Parkinson’s
disease, and amyotrophic lateral sclerosis. Biogen also manufactures and
commercializes biosimilars of advanced biologics. For more information,
please visit
Follow us on social media – Twitter,

Biogen Safe Harbor
This press release contains
forward-looking statements, made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including
statements relating to Biogen’s business activities, the potential of
Biogen’s commercial business and pipeline programs, , and the expected
benefits from Ms. Lee’s appointment as our Senior Vice President,
Alzheimer’s Therapeutic Area. These forward-looking statements may be
accompanied by words such as “aim,” “anticipate,” “believe,” “could,”
“estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,”
“possible,” “will,” and other words and terms of similar meaning. Drug
development and commercialization involve a high degree of risk, and
only a small number of research and development programs result in
commercialization of a product. You should not place undue reliance on
these statements.

These statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including, without limitation: risks relating to management and key
personnel changes; failure to compete effectively; difficulties in
obtaining and maintaining adequate coverage, pricing, and reimbursement
for our products; potential future healthcare reforms; the occurrence of
adverse safety events; failure to protect and enforce our data,
intellectual property, and other proprietary rights and uncertainties
relating to intellectual property claims and challenges; uncertainty of
success in developing, licensing, or acquiring other product candidates
or additional indications for existing products; delay in approval of
our drug candidates; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of the
factors that could cause actual results to differ from our expectations
in any forward-looking statement. Investors should consider this
cautionary statement, as well as the risk factors identified in Biogen’s
most recent annual or quarterly report and in other reports Biogen has
filed with the U.S. Securities and Exchange Commission. These statements
are based on our current beliefs and expectations and speak only as of
the date of this press release. We do not undertake any obligation to
publicly update any forward-looking statements, whether as a result of
new information, future developments or otherwise.

Read more

Leave A Comment

Your email address will not be published. Required fields are marked *